Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Confirmed diagnosis of Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase :
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score 0 - 1
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
35 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal